A homologous membrane-camouflaged self-assembled nanodrug for synergistic antitumor therapy

Limited success has been achieved in ferroptosis-induced Cancer treatment due to the challenges related to low production of toxic Reactive Oxygen Species (ROS) and inherent ROS resistance in Cancer cells. To address this issue, a self-assembled nanodrug have been investigated that enhances Ferroptosis therapy by increasing ROS production and reducing ROS inhibition. The nanodrug is constructed by allowing doxorubicin (DOX) to interact with Fe²⁺ through coordination interactions, forming a stable DOX-Fe²⁺ chelate, and this chelate further interacts with sorafenib (SRF), resulting in a stable and uniform nanoparticle. In tumor cells, overexpressed glutathione (GSH) triggers the disassembly of nanodrug, thereby activating the drug release. Interestingly, the released DOX not only activates nicotinamide adenine dinucleotide phosphate oxidase 4 (NOX4) to produce abundant H₂O₂ production for enhanced ROS production, but also acts as a chemotherapeutics agent, synergizing with Ferroptosis. To enhance tumor selectivity and improve the blood clearance, the nanodrug is coated with a related Cancer cell membrane, which enhances the selective inhibition of tumor growth and metastasis in a B16F10 mice model. Our findings provide valuable insights into the rational design of self-assembled nanodrug for enhanced Ferroptosis therapy in Cancer treatment. STATEMENT OF SIGNIFICANCE: Ferroptosis is a non-apoptotic form of cell death induced by the iron-regulated lipid peroxides (LPOs), offering a promising potential for effective and safe anti-cancer treatment. However, two significant challenges hinder its clinical application: 1) The easily oxidized nature of Fe2+ and the low concentration of H₂O₂ leads to a low efficiency of intracellular Fenton reaction, resulting in poor therapeutic efficacy; 2) The instinctive ROS resistance of Cancer cells induce drug resistance. Therefore, we developed a simple and high-efficiency nanodrug composed of self-assembling by Fe²⁺ sources, H₂O₂ inducer and ROS resistance inhibitors. This nanodrug can effectively deliver the Fe²⁺ sources into tumor tissue, enhance intracellular concentration of H2O2, and reduce ROS resistance, achieving a high-efficiency, precise and safe Ferroptosis therapy.

Cancer cell membrane; Chemotherapy; Ferroptosis; ROS resistance; Self-assembled nanodrug.